Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Horvath

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Future Oncology (London, England)|January 17, 2025
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)Ciara Conduit, Andrisha-Jade Inderjeeth, Raymond Allen, et al.
Cancer Cell|February 13, 2019
DNA Hypermethylation Encroachment at CpG Island Borders in Cancer Is Predisposed by H3K4 Monomethylation PatternsKsenia Skvortsova, Etienne Masle-Farquhar, Phuc-Loi Luu, et al.
Nature Medicine|March 7, 2025
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trialJeanne Tie, Yuxuan Wang, Serigne N Lo, et al.
Genome Medicine|May 11, 2021
Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysisSunny Z Wu, Daniel L Roden, Ghamdan Al-Eryani, et al.
The Lancet. Oncology|April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Nature Communications|June 13, 2018
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variantsTokhir Dadaev, Edward J Saunders, Paul J Newcombe, et al.
Nature Genetics|January 10, 2019
Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility lociFredrick R Schumacher, Ali Amin Al Olama, Sonja I Berndt, et al.
Nature Genetics|June 13, 2018
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility lociFredrick R Schumacher, Ali Amin Al Olama, Sonja I Berndt, et al.
Nature Genetics|January 5, 2021
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk predictionDavid V Conti, Burcu F Darst, Lilit C Moss, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Future Oncology (London, England)|January 17, 2025
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)Ciara Conduit, Andrisha-Jade Inderjeeth, Raymond Allen, et al.
Cancer Cell|February 13, 2019
DNA Hypermethylation Encroachment at CpG Island Borders in Cancer Is Predisposed by H3K4 Monomethylation PatternsKsenia Skvortsova, Etienne Masle-Farquhar, Phuc-Loi Luu, et al.
Nature Medicine|March 7, 2025
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trialJeanne Tie, Yuxuan Wang, Serigne N Lo, et al.
Genome Medicine|May 11, 2021
Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysisSunny Z Wu, Daniel L Roden, Ghamdan Al-Eryani, et al.
The Lancet. Oncology|April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Nature Communications|June 13, 2018
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variantsTokhir Dadaev, Edward J Saunders, Paul J Newcombe, et al.
Nature Genetics|January 10, 2019
Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility lociFredrick R Schumacher, Ali Amin Al Olama, Sonja I Berndt, et al.
Nature Genetics|June 13, 2018
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility lociFredrick R Schumacher, Ali Amin Al Olama, Sonja I Berndt, et al.
Nature Genetics|January 5, 2021
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk predictionDavid V Conti, Burcu F Darst, Lilit C Moss, et al.
Pageof 5